Announcements Trials

Browse Landscape

Phase

Phase 3 4 Phase 2 2 Phase NA 1 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 3 Prostatic Neoplasms 1 Polyps 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 NSCLC 1 Multiple Myeloma 1 Mouth Neoplasms 1 Breast Neoplasms 1 Aggressive Periodontitis 1 Adenomatous Polyps 1 Adenoma 1

Interventions

Docetaxel 7 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5 Prednisone 5 Androgen Antagonists 5 gallium 68 PSMA-11 4 enzalutamide 3 bicalutamide 3 Triptorelin Pamoate 3 Radiosurgery 3 Leuprolide 3 Goserelin 3 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3 abiraterone 2 Zoledronic Acid 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Mitoxantrone 2 Flutamide 2 Celecoxib 2 Abiraterone Acetate 2 satraplatin 1 relugolix 1 pertuzumab 1 nilutamide 1 maltodextrin 1 luprolide acetate gel depot 1 histrelin 1 genistein combined polysaccharide 1 fluciclovine F-18 1 darolutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Prostatic Neoplasms × Aspirin × Clear all

NCT03103152 2023-03-29

PROVENT

Queen Mary University of London

Phase 2/3 Completed

104 enrolled 14 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡